Celltrion cruising to launch Truxima with nullifying relevant patents in Korea

Celltrion announced the Intellectual Property Tribunal ruled patent nullification related to an original ‘Rituxan’ patent owned by Biogen on the 23^rd of August.

In order to commercialize a Rituxan’s(Mabthera) biosimilar, ‘Truxima,’ Celltrion has once applied for a patent nullification suit on patents owned by Genentech and Biogen. Celltrion is planning to work on the commercialization as judgi...